Mark Bach
Chief Medical Officer GentiBio
Seminars
Wednesday 2nd December 2026
Early-Phase Clinical Evaluation of GNTI-122, an Engineered Regulatory T-Cell Therapy, in Recent- Onset Type 1 Diabetes
11:00 am
- Evaluating early efficacy signals from proof-of-concept trials to guide development decisions
- Optimizing trial design and patient stratification to strengthen clinical proof-of-concept
- Integrating clinical insights with regulatory and operational strategies to accelerate progress
